Rebecca Jaslow

TitleAssoc Professor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-8874
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Abu-Khalaf M, Wang C, Zhang Z, Luo R, Chong W, Silver DP, Fellin F, Jaslow R, Lopez A, Cescon T, Jiang W, Myers R, Wei Q, Li B, Cristofanilli M, Yang H. Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. Cancers (Basel). 2022 Jun 10; 14(12). PMID: 35740538.
      Citations:    
    2. Wang C, Mu Z, Ye Z, Zhang Z, Abu-Khalaf MM, Silver DP, Palazzo JP, Jagannathan G, Fellin FM, Bhattacharya S, Jaslow RJ, Tsangaris TN, Berger A, Neupane M, Cescon TP, Lopez A, Yao K, Chong W, Lu B, Myers RE, Hou L, Wei Q, Li B, Cristofanilli M, Yang H. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020 May 04. PMID: 32367460.
      Citations:    
    3. Laufer T, Lerner B, Petrich A, Quinn AM, Ernst L, Roop A, Knoblauch J, Leasure NC, Jaslow RJ, Hegarty S, Leader A, Barsevick A. Evaluation of a Technology-Based Survivor Care Plan for Breast Cancer Survivors: Pre-Post Pilot Study. JMIR Cancer. 2019 Dec 20; 5(2):e12090. PMID: 31859683.
      Citations:    
    4. Ye Z, Wang C, Wan S, Mu Z, Zhang Z, Abu-Khalaf MM, Fellin FM, Silver DP, Neupane M, Jaslow RJ, Bhattacharya S, Tsangaris TN, Chervoneva I, Berger A, Austin L, Palazzo JP, Myers RE, Pancholy N, Toorkey D, Yao K, Krall M, Li X, Chen X, Fu X, Xing J, Hou L, Wei Q, Li B, Cristofanilli M, Yang H. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. Eur J Cancer. 2019 Jan; 106:133-143. PMID: 30528798.
      Citations:    
    5. Toss A, Palazzo J, Berger A, Guiles F, Sendecki JA, Simone N, Anne R, Avery T, Jaslow R, Lazar M, Tsangaris T, Cristofanilli M. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. Breast. 2016 Oct; 29:223-30. PMID: 27506636.
      Citations:    
    6. Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat. 2015 Dec; 154(3):563-71. PMID: 26573830.
      Citations:    
    7. Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY. Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation. Breast J. 2013 May; 19(3):269-75. PMID: 23614365.
      Citations:    
    Co-Authors (22)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _